Cyclophosphamide, adriamycin and cisplatin (CAP) versus cyclophosphamide, adriamycin and vincristin (CAV) in the treatment of advanced ovarian cancer: a randomized study.
Two combinations of chemotherapy agents were compared for therapeutic effectiveness on 83 patients with advanced ovarian carcinoma (stages III and IV) in a prospective single-blind randomized trial. Forty-two patients were treated with cyclophosphamide, adriamycin, and vincristin (CAV), and 41 patients were treated with cyclophosphamide, adriamycin, and cisplatin (CAP). In the CAP treated group 34 (82.9%) and in the CAV treated group 23 (54.8%) responded to cytostatic therapy. The median progression free interval was longer in the CAP (14 months) than in the CAV (10 months) treatment group. The median survival was 24 months and 15 months in favor of the CAP therapy. The log-rank and Wilcoxon statistics for the comparison of the progression free interval and survival curves indicated statistically significant therapeutic advantages for the CAP treatment combination.